REM-话题@MedSci

#REM#

111篇内容 | 2804人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1752297, encodeId=c72b1e522973c, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=TREMFYA（guselkumab）治疗成人银屑病关节炎：显著减少了疲劳症状, objectType=article, longId=203134, objectId=b12e2031349b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b12e2031349b, replyNumber=0, likeNumber=79, createdTime=2021-01-28, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b12e2031349b, moduleTitle=TREMFYA（guselkumab）治疗成人银屑病关节炎：显著减少了疲劳症状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b12e2031349b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752290, encodeId=92981e522903b, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=CELL：TREM2可增强肿瘤抗PD-1免疫治疗效果 , objectType=article, longId=199294, objectId=7bfe199294c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7bfe199294c1, replyNumber=0, likeNumber=82, createdTime=2021-06-26, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7bfe199294c1, moduleTitle=CELL：TREM2可增强肿瘤抗PD-1免疫治疗效果 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7bfe199294c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752287, encodeId=3d2f1e5228767, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=基因疗法beremagene geperpavec治疗营养不良性大疱性表皮松解症：即将开展III期临床, objectType=article, longId=198352, objectId=6b7c198352b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b7c198352b0, replyNumber=0, likeNumber=77, createdTime=2020-11-21, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b7c198352b0, moduleTitle=基因疗法beremagene geperpavec治疗营养不良性大疱性表皮松解症：即将开展III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b7c198352b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752299, encodeId=1bf91e5229990, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=欧盟委员会批准了TREMFYA®（guselkumab）治疗活动性银屑病关节炎（PsA）, objectType=article, longId=203779, objectId=0bb5203e7985, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bb5203e7985, replyNumber=0, likeNumber=104, createdTime=2021-03-17, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bb5203e7985, moduleTitle=欧盟委员会批准了TREMFYA®（guselkumab）治疗活动性银屑病关节炎（PsA）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bb5203e7985)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752301, encodeId=46dc1e5230195, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=BRAIN：REM睡眠行为障碍和随后的帕金森氏表型, objectType=article, longId=205167, objectId=216720516ee7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=216720516ee7, replyNumber=0, likeNumber=50, createdTime=2021-08-10, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=216720516ee7, moduleTitle=BRAIN：REM睡眠行为障碍和随后的帕金森氏表型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=216720516ee7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752278, encodeId=b5781e52278d1, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=Otezla（apremilast）治疗轻中度斑块型牛皮癣的III期ADVANCE研究：取得积极结果, objectType=article, longId=193626, objectId=9c621936262c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c621936262c, replyNumber=0, likeNumber=78, createdTime=2020-11-04, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c621936262c, moduleTitle=Otezla（apremilast）治疗轻中度斑块型牛皮癣的III期ADVANCE研究：取得积极结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c621936262c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752292, encodeId=f8641e522921e, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=Acta Neuropathologica: 在MS模型中，小胶质细胞上的TREM2激活促进髓鞘碎片清除和髓鞘再形成, objectType=article, longId=200990, objectId=425520099070, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=425520099070, replyNumber=0, likeNumber=69, createdTime=2020-10-23, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=425520099070, moduleTitle=Acta Neuropathologica: 在MS模型中，小胶质细胞上的TREM2激活促进髓鞘碎片清除和髓鞘再形成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=425520099070)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752296, encodeId=d1091e52296ff, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=BMS口服TYK2抑制剂deucravacitinib治疗斑块型银屑病3期临床成功! 效果优于apremilast, objectType=article, longId=202961, objectId=601d202961a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=601d202961a3, replyNumber=0, likeNumber=78, createdTime=2021-06-10, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=601d202961a3, moduleTitle=BMS口服TYK2抑制剂deucravacitinib治疗斑块型银屑病3期临床成功! 效果优于apremilast, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=601d202961a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752298, encodeId=56b81e52298fe, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=世界**重症监护机构建议：重症新冠COVID-19感染患者不要使用remdesivir, objectType=article, longId=203469, objectId=922920346906, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=922920346906, replyNumber=0, likeNumber=72, createdTime=2021-08-27, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=922920346906, moduleTitle=世界**重症监护机构建议：重症新冠COVID-19感染患者不要使用remdesivir, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=922920346906)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752302, encodeId=6fd41e5230226, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=MSI/IHC和PREMM5可筛选Lynch综合征相关结直肠和子宫内膜癌, objectType=article, longId=206099, objectId=bb9220609963, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb9220609963, replyNumber=0, likeNumber=75, createdTime=2021-08-24, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb9220609963, moduleTitle=MSI/IHC和PREMM5可筛选Lynch综合征相关结直肠和子宫内膜癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb9220609963)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752303, encodeId=948b1e52303a0, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=Clin Cancer Res：Durvalumab+Tremelimumab+放疗用于错配修复正常的转移性结直肠癌的疗效, objectType=article, longId=206790, objectId=0006206e9068, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0006206e9068, replyNumber=0, likeNumber=111, createdTime=2021-12-17, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0006206e9068, moduleTitle=Clin Cancer Res：Durvalumab+Tremelimumab+放疗用于错配修复正常的转移性结直肠癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0006206e9068)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752286, encodeId=f5951e52286f2, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=Nat Commun ：张骏组揭示下丘脑orexin神经系统在REM睡眠稳定维持中的重要作用, objectType=article, longId=198093, objectId=236e198093a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=236e198093a2, replyNumber=0, likeNumber=112, createdTime=2020-09-27, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=236e198093a2, moduleTitle=Nat Commun ：张骏组揭示下丘脑orexin神经系统在REM睡眠稳定维持中的重要作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=236e198093a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752274, encodeId=c4451e5227440, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=欧洲药品管理局（EMA）：允许“同情使用”瑞德西韦（remdesivir）治疗COVID-19, objectType=article, longId=191467, objectId=538b19146ee0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=538b19146ee0, replyNumber=0, likeNumber=70, createdTime=2020-04-26, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=538b19146ee0, moduleTitle=欧洲药品管理局（EMA）：允许“同情使用”瑞德西韦（remdesivir）治疗COVID-19, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=538b19146ee0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752282, encodeId=876e1e5228293, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=Remdesivir成为获得欧盟推荐的抗COVID-19药物, objectType=article, longId=196573, objectId=39ef1965e393, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39ef1965e393, replyNumber=0, likeNumber=65, createdTime=2020-10-15, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39ef1965e393, moduleTitle=Remdesivir成为获得欧盟推荐的抗COVID-19药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39ef1965e393)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752268, encodeId=e3de1e52268ff, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=瑞德西韦（Remdesivir）治疗新冠肺炎受试者招募广告, objectType=article, longId=187825, objectId=d64718e825fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d64718e825fb, replyNumber=0, likeNumber=64, createdTime=2020-10-28, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d64718e825fb, moduleTitle=瑞德西韦（Remdesivir）治疗新冠肺炎受试者招募广告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d64718e825fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752276, encodeId=17ca1e5227691, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=斑块状银屑病重大进展！西安杨森Tremfya(特诺雅，古塞奇尤单抗)获国家药监局(NMPA)批准上市！, objectType=article, longId=192695, objectId=249d19269580, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=249d19269580, replyNumber=0, likeNumber=69, createdTime=2020-09-25, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=249d19269580, moduleTitle=斑块状银屑病重大进展！西安杨森Tremfya(特诺雅，古塞奇尤单抗)获国家药监局(NMPA)批准上市！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=249d19269580)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752262, encodeId=f41e1e522626b, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=抗击2019-nCoV：实验性埃博拉药物Remdesivir或具有抗新型冠状病毒的潜力, objectType=article, longId=186733, objectId=abd8186e3334, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=abd8186e3334, replyNumber=0, likeNumber=81, createdTime=2020-10-04, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=abd8186e3334, moduleTitle=抗击2019-nCoV：实验性埃博拉药物Remdesivir或具有抗新型冠状病毒的潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=abd8186e3334)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752295, encodeId=6ec01e522958c, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=TREMFYA（guselkumab）治疗活动性银屑病关节炎（PsA）：已获得CHMP的积极意见, objectType=article, longId=202280, objectId=18ae2022800c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18ae2022800c, replyNumber=0, likeNumber=72, createdTime=2021-04-13, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18ae2022800c, moduleTitle=TREMFYA（guselkumab）治疗活动性银屑病关节炎（PsA）：已获得CHMP的积极意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18ae2022800c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752279, encodeId=b6351e5227918, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=日本批准瑞德西韦（remdesivir）治疗重度COVID-19患者, objectType=article, longId=193808, objectId=7ade193808a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7ade193808a1, replyNumber=0, likeNumber=65, createdTime=2020-08-29, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7ade193808a1, moduleTitle=日本批准瑞德西韦（remdesivir）治疗重度COVID-19患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7ade193808a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1752267, encodeId=f09c1e5226729, content=<a href='/topic/show?id=28a915303ec' target=_blank style='color:#2F92EE;'>#REM#</a>, objectTitle=Remdesivir(瑞德西韦)的临床试验昨日并未入组200例患者, objectType=article, longId=187453, objectId=274618e45370, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=274618e45370, replyNumber=0, likeNumber=54, createdTime=2020-09-04, rootId=0, userName=tongyongming, userId=78bc36479935, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=274618e45370, moduleTitle=Remdesivir(瑞德西韦)的临床试验昨日并未入组200例患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=274618e45370)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

REM

2020-05-29

tongyongming (审核中...)

前往app查看评论内容

#REM#

TREMFYA（guselkumab）治疗成人银屑病关节炎：显著减少了疲劳症状

2021-01-28

tongyongming (审核中...)

前往app查看评论内容

#REM#

CELL：TREM2可增强肿瘤抗PD-1免疫治疗效果

2021-06-26

tongyongming (审核中...)

前往app查看评论内容

#REM#

基因疗法beremagene geperpavec治疗营养不良性大疱性表皮松解症：即将开展III期临床

2020-11-21

tongyongming (审核中...)

前往app查看评论内容

#REM#

欧盟委员会批准了TREMFYA®（guselkumab）治疗活动性银屑病关节炎（PsA）

2021-03-17

tongyongming (审核中...)

前往app查看评论内容

#REM#

BRAIN：REM睡眠行为障碍和随后的帕金森氏表型

2021-08-10

tongyongming (审核中...)

前往app查看评论内容

#REM#

Otezla（apremilast）治疗轻中度斑块型牛皮癣的III期ADVANCE研究：取得积极结果

2020-11-04

tongyongming (审核中...)

前往app查看评论内容

#REM#

Acta Neuropathologica: 在MS模型中，小胶质细胞上的TREM2激活促进髓鞘碎片清除和髓鞘再形成

2020-10-23

tongyongming (审核中...)

前往app查看评论内容

#REM#

BMS口服TYK2抑制剂deucravacitinib治疗斑块型银屑病3期临床成功! 效果优于apremilast

2021-06-10

tongyongming (审核中...)

前往app查看评论内容

#REM#

世界**重症监护机构建议：重症新冠COVID-19感染患者不要使用remdesivir

2021-08-27

tongyongming (审核中...)

前往app查看评论内容

#REM#

MSI/IHC和PREMM5可筛选Lynch综合征相关结直肠和子宫内膜癌

2021-08-24

tongyongming (审核中...)

前往app查看评论内容

#REM#

Clin Cancer Res：Durvalumab+Tremelimumab+放疗用于错配修复正常的转移性结直肠癌的疗效

2021-12-17

tongyongming (审核中...)

前往app查看评论内容

#REM#

Nat Commun ：张骏组揭示下丘脑orexin神经系统在REM睡眠稳定维持中的重要作用

2020-09-27

tongyongming (审核中...)

前往app查看评论内容

#REM#

欧洲药品管理局（EMA）：允许“同情使用”瑞德西韦（remdesivir）治疗COVID-19

2020-04-26

tongyongming (审核中...)

前往app查看评论内容

#REM#

Remdesivir成为获得欧盟推荐的抗COVID-19药物

2020-10-15

tongyongming (审核中...)

前往app查看评论内容

#REM#

瑞德西韦（Remdesivir）治疗新冠肺炎受试者招募广告

2020-10-28

tongyongming (审核中...)

前往app查看评论内容

#REM#

斑块状银屑病重大进展！西安杨森Tremfya(特诺雅，古塞奇尤单抗)获国家药监局(NMPA)批准上市！

2020-09-25

tongyongming (审核中...)

前往app查看评论内容

#REM#

抗击2019-nCoV：实验性埃博拉药物Remdesivir或具有抗新型冠状病毒的潜力

2020-10-04

tongyongming (审核中...)

前往app查看评论内容

#REM#

TREMFYA（guselkumab）治疗活动性银屑病关节炎（PsA）：已获得CHMP的积极意见

2021-04-13

tongyongming (审核中...)

前往app查看评论内容

#REM#

日本批准瑞德西韦（remdesivir）治疗重度COVID-19患者

2020-08-29

tongyongming (审核中...)

前往app查看评论内容

#REM#

Remdesivir(瑞德西韦)的临床试验昨日并未入组200例患者

2020-09-04

科室
- - 订阅+
  - 更多科室
工具
服务